TrialGlobe

Clinical trial

Characterization and Phenotyping of Patients Who Are Offered Drug Therapy for Obesity

Recruiting now · Not applicable · 1 countries · Registry ID NCT07414043

Recruiting nowNot applicableObservational

What this study is about

The study is multicenter and observational, consisting of a cross-sectional phase (V0) in which data will be collected from patients who are offered drug therapy, and a prospective longitudinal phase in which only patients who agree to start drug therapy for obesity will be involved

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age12 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionObesity & Overweight

Full registry criteria

Inclusion Criteria: Age ≥ 12 years * Therapeutic indication for taking one of the following drugs for the treatment of obesity: Orlistat, Naltrexone/Bupropion (Mysimba®), Liraglutide (Saxenda®), Semaglutide (Wegovy®), Tirzepatide (Mounjaro®) Exclusion Criteria: - Type 1 and type 2 diabetes mellitus \- Secondary forms of obesity: * Hypothalamic obesity (both monogenic and acquired forms); * Syndromic obesity (e.g., Prader-Willi, Alstrom, Bardet Biedl, etc.); * Endocrinopathies associated with obesity (Cushing's syndrome, uncompensated hypothyroidism)

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

The primary objective is to identify the proportion and medical history, social, clinical, laboratory, and behavioral characteristics of patients who accept a prescription for a drug for overweight and obesity compared to the total number of patients10 years

The primary objective is to identify the proportion and medical history, social, clinical, laboratory, and behavioral characteristics of patients who accept a prescription for a drug for overweight and obesity compared to the total number of patients to whom it is proposed. These parameters will be monitored with regular follow-ups for up to 5 years after the start of therapy or 12 months after discontinuation of the drug. Descriptive statistics will be used to verify the primary objective. The demographic and clinical characteristics of patients will be reported as frequencies and percentages for categorical variables and as mean ± standard deviation or median and range for continuous variables.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

IRCCS Azienda Ospedaliero-Universitaria di Bologna🇮🇹 Bologna, Bologna, Italy
Open map
Uberto Pagotto, MDContact
Email · Call 0512144190